<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224337</url>
  </required_header>
  <id_info>
    <org_study_id>PSC2</org_study_id>
    <nct_id>NCT04224337</nct_id>
  </id_info>
  <brief_title>Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma</brief_title>
  <official_title>Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of durvalumab in combination with doxorubicin and&#xD;
      ifosfamide in patients with PSC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II multi-center, open-label study to evaluate the efficacy and safety of&#xD;
      durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate (RR)</measure>
    <time_frame>24 months</time_frame>
    <description>modified RECIST1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>24 months</time_frame>
    <description>number of patients with treatment-related AE as assessed by NCI CTCAE</description>
  </secondary_outcome>
  <other_outcome>
    <measure>biomarker</measure>
    <time_frame>24 months</time_frame>
    <description>Correlation with C-MET mutation, PD-L1 IHC</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + doxorubicin + ifosfamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab + doxorubicin + ifosfamide</intervention_name>
    <description>Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed NSCLC with the histology of sarcomatoid&#xD;
             carcinoma (WHO criteria for sarcomatoid carcinoma is used; carcinoma with spindle&#xD;
             and/or giant cells, pleomorphic carcinoma, spindle cell carcinoma, giant cell&#xD;
             carcinoma, carcinosarcoma, pulmonary blastoma). If the NSCLC patients showed&#xD;
             sarcomatoid carcinoma histology in re-biopsy sample (so called epithelial-mesenchymal&#xD;
             transition (EMT) phenomenon), such patients are eligible.&#xD;
&#xD;
          2. Age ≥ 20 years at time of study entry.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          4. Initial metastatic cases or recurrent cases after curative treatment (up to 2 previous&#xD;
             lines are allowed, and patients who experienced immune-checkpoint inhibitors are also&#xD;
             allowed).&#xD;
&#xD;
          5. A patient with at least one measurable lesion by RECIST1.1.&#xD;
&#xD;
          6. Asymptomatic brain metastasis. If patients have brain metastasis with neurological&#xD;
             symptom, they should be stabilized neurologically with prior radiotherapy or surgery&#xD;
             for the brain metastasis.&#xD;
&#xD;
          7. Body weight &gt;40kg&#xD;
&#xD;
          8. Adequate normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Haemoglobin ≥9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500 /mm3&#xD;
&#xD;
               -  Platelet count ≥100,000 /mm3&#xD;
&#xD;
               -  Serum bilirubin ≤1.5 x upper limit of normal (ULN).&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which&#xD;
                  case it must be ≤5x ULN&#xD;
&#xD;
               -  Measured creatinine clearance (CL) &gt;40 mL/min or Calculated creatinine CL&gt;40&#xD;
                  mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976)&#xD;
&#xD;
          9. Evidence of post-menopausal status or negative urinary or serum pregnancy test for&#xD;
             female pre-menopausal patients. Women will be considered post-menopausal if they have&#xD;
             been amenorrheic for 12 months without an alternative medical cause. The following&#xD;
             age-specific requirements apply:&#xD;
&#xD;
             Women &lt;50 years of age would be considered post-menopausal if they have been&#xD;
             amenorrheic for 12 months or more following cessation of exogenous hormonal treatments&#xD;
             and if they have luteinizing hormone and follicle-stimulating hormone levels in the&#xD;
             post-menopausal range for the institution or underwent surgical sterilization&#xD;
             (bilateral oophorectomy or hysterectomy). Women ≥50 years of age would be considered&#xD;
             post-menopausal if they have been amenorrheic for 12 months or more following&#xD;
             cessation of all exogenous hormonal treatments, had radiation-induced menopause with&#xD;
             last menses &gt;1 year ago, had chemotherapy-induced menopause with last menses &gt;1 year&#xD;
             ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral&#xD;
             salpingectomy or hysterectomy).&#xD;
&#xD;
         10. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
         11. Must have a life expectancy of at least 12 weeks.&#xD;
&#xD;
         12. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol. Written informed consent and any locally required authorization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical study with an investigational product during the&#xD;
             last 3weeks.&#xD;
&#xD;
          2. A patient with no measurable disease.&#xD;
&#xD;
          3. History of diverticulitis, intra-abdominal abscess, gastrointestinal obstruction,&#xD;
             abdominal carcinomatosis which are known risks factors for bowel perforation.&#xD;
&#xD;
          4. Active autoimmune disease within the past 2 years (NOTE: Subjects with vitiligo,&#xD;
             Grave's disease, or psoriasis not requiring systemic treatment -within the past 2&#xD;
             years- are not excluded) or a documented history of autoimmune disease or syndrome&#xD;
             that requires systemic steroids or immunosuppressive agents.&#xD;
&#xD;
          5. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine&#xD;
             therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal&#xD;
             antibodies) ≤ 3 weeks prior to the first dose of study drug If sufficient wash-out&#xD;
             time has not occurred due to the schedule or PK properties of an agent, a longer&#xD;
             wash-out period will be required, as agreed by AstraZeneca/MedImmune and the&#xD;
             investigator.&#xD;
&#xD;
          6. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria.&#xD;
&#xD;
               1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after&#xD;
                  consultation with the Study Physician.&#xD;
&#xD;
               2. Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab may be included only after consultation with the Study&#xD;
                  Physician.&#xD;
&#xD;
          7. Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment. Concurrent&#xD;
             use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement&#xD;
             therapy) is acceptable.&#xD;
&#xD;
          8. Major surgical procedure (as defined by the Investigator) within 28 days prior to the&#xD;
             first dose of IP. Note: Local surgery of isolated lesions for palliative intent is&#xD;
             acceptable.&#xD;
&#xD;
          9. History of allogenic organ transplantation.&#xD;
&#xD;
         10. Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid.&#xD;
&#xD;
         11. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               1. Patients with vitiligo or alopecia&#xD;
&#xD;
               2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               3. Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               4. Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               5. Patients with celiac disease controlled by diet alone&#xD;
&#xD;
         12. Uncontrolled current illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring AEs or compromise the ability of the patient to give written&#xD;
             informed consent.&#xD;
&#xD;
         13. History of another primary malignancy except for&#xD;
&#xD;
               1. Malignancy treated with curative intent and with no known active disease ≥5 years&#xD;
                  before the first dose of IP&#xD;
&#xD;
               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               3. Adequately treated carcinoma in situ without evidence of disease, NED ≥3 years&#xD;
&#xD;
         14. History of cytologically proven leptomeningeal carcinomatosis&#xD;
&#xD;
         15. QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms&#xD;
             calculated from 3 ECG&#xD;
&#xD;
         16. A patient with clinically significant (i.e. active) heart disease (e.g.congestive&#xD;
             heart failure, symptomatic coronary artery diseases, cardiac arrhythmias, etc) or&#xD;
             myocardial infarction within past 12 months.&#xD;
&#xD;
         17. History of active primary immunodeficiency.&#xD;
&#xD;
         18. Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),&#xD;
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients&#xD;
             with a past or resolved HBV infection (defined as the presence of hepatitis B core&#xD;
             antibody [anti-HBc] and absence of HBsAg) and with appropriate prophylactic antiviral&#xD;
             agents for positive HbsAg are eligible. Patients positive for hepatitis C (HCV)&#xD;
             antibody are eligible only if polymerase chain reaction is negative for HCV RNA.&#xD;
&#xD;
         19. Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of durvalumab. The following are exceptions to this criterion:&#xD;
&#xD;
               1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection)&#xD;
&#xD;
               2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or its equivalent&#xD;
&#xD;
               3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
&#xD;
         20. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:&#xD;
             Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to&#xD;
             30 days after the last dose of IP.&#xD;
&#xD;
         21. Female patients who are pregnant or breastfeeding or male or female patients of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 180 days after the last dose of durvalumab monotherapy.&#xD;
&#xD;
         22. Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients.&#xD;
&#xD;
         23. Judgment by the investigator that the patient is unsuitable to participate in the&#xD;
             study and the patient is unlikely to comply with study procedures, restrictions and&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhumsuk Keam, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhumsuk Keam, Ph.D.</last_name>
    <phone>82220727215</phone>
    <email>bhumsuk@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhumsuk Keam</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Bhumsuk Keam</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>anticipated as research paper</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

